Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients
Authors
Keywords
Biomarkers, Circulating tumor cells, CTCs, Personalized treatment, Prostate cancer, Treatment efficacy
Journal
BMC CANCER
Volume 15, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-06-08
DOI
10.1186/s12885-015-1478-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Optimisation of an immunohistochemistry method for the determination of androgen receptor expression levels in circulating tumour cells
- (2014) Jeffrey Cummings et al. BMC CANCER
- Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients
- (2014) Markus Wallwiener et al. BMC CANCER
- Circulating tumour cells—a bona fide cause of metastatic cancer
- (2014) N. J. Caixeiro et al. CANCER AND METASTASIS REVIEWS
- Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer
- (2014) Amir Goldkorn et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating tumour cells—monitoring treatment response in prostate cancer
- (2014) David T. Miyamoto et al. Nature Reviews Clinical Oncology
- Interpretation of Changes in Circulating Tumor Cell Counts
- (2014) Frank A.W. Coumans et al. Translational Oncology
- Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)
- (2014) Eva Gupta et al. BMC Urology
- Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
- (2014) Atsushi Tomioka et al. BMC Urology
- External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
- (2014) Kazuhiko Nakano et al. BMC Urology
- Method validation of circulating tumour cell enumeration at low cell counts
- (2013) Jeffrey Cummings et al. BMC CANCER
- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
- (2013) Axel Heidenreich et al. EUROPEAN UROLOGY
- New frontiers in circulating tumor cell analysis: A reference guide for biomolecular profiling toward translational clinical use
- (2013) Therese M. Becker et al. INTERNATIONAL JOURNAL OF CANCER
- Detection of circulating tumor cells in different stages of prostate cancer
- (2013) Mark Thalgott et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer
- (2012) Mark Jesus M Magbanua et al. BMC CANCER
- Detection of Lipid-Rich Prostate Circulating Tumour Cells with Coherent Anti-Stokes Raman Scattering Microscopy
- (2012) Ranjana Mitra et al. BMC CANCER
- Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures
- (2012) Xuan Huang et al. Journal of Hematology & Oncology
- Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients
- (2012) Andreia de Albuquerque et al. Journal of Translational Medicine
- Considerations in the development of circulating tumor cell technology for clinical use
- (2012) David R Parkinson et al. Journal of Translational Medicine
- Prognostic Significance of Circulating Tumor Cell Count in Patients With Metastatic Hormone-sensitive Prostate Cancer
- (2012) Luis Resel Folkersma et al. UROLOGY
- Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer
- (2012) David T. Miyamoto et al. Cancer Discovery
- The Potential of Circulating Tumor Cells as a Liquid Biopsy to Guide Therapy in Prostate Cancer
- (2012) Klaus Pantel et al. Cancer Discovery
- Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer
- (2011) Satoshi Matsusaka et al. CANCER SCIENCE
- Comparison of Circulating MicroRNA 141 to Circulating Tumor Cells, Lactate Dehydrogenase, and Prostate-Specific Antigen for Determining Treatment Response in Patients With Metastatic Prostate Cancer
- (2011) Jason C. Gonzales et al. Clinical Genitourinary Cancer
- Circulating Tumor Cells as a Predictive Biomarker in Patients With Hormone-sensitive Prostate Cancer
- (2011) Oscar B. Goodman et al. Clinical Genitourinary Cancer
- Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer
- (2011) Andrew J. Armstrong et al. EUROPEAN UROLOGY
- Increases in Quantitative D-Dimer Levels Correlate With Progressive Disease Better Than Circulating Tumor Cell Counts in Patients With Refractory Prostate Cancer
- (2010) Joseph D. Khoury et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel
- (2010) M.H. Strijbos et al. EUROPEAN JOURNAL OF CANCER
- Imaging Studies in Metastatic Urogenital Cancer Patients Undergoing Systemic Therapy: Recommendations of a Multidisciplinary Consensus Meeting of the Association of Urological Oncology of the German Cancer Society
- (2010) Axel Heidenreich et al. UROLOGIA INTERNATIONALIS
- Imaging metastatic bone disease from carcinoma of the prostate
- (2009) C Messiou et al. BRITISH JOURNAL OF CANCER
- Circulating Tumor Cells in Patients with Castration-Resistant Prostate Cancer Baseline Values and Correlation with Prognostic Factors
- (2009) O. B. Goodman et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Circulating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast Cancer
- (2009) Minetta C. Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Significance of Circulating Tumor Cells in Patients With Hormone Refractory Prostate Cancer
- (2009) Takatsugu Okegawa et al. JOURNAL OF UROLOGY
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
- (2009) Howard I Scher et al. LANCET ONCOLOGY
- Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience
- (2008) D. Olmos et al. ANNALS OF ONCOLOGY
- Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study
- (2008) D. R. Berthold et al. CLINICAL CANCER RESEARCH
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
- (2008) J. S. de Bono et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer
- (2008) Steven J. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunomagnetic Quantification of Circulating Tumor Cells as a Prognostic Factor of Androgen Deprivation Responsiveness in Patients With Hormone Naive Metastatic Prostate Cancer
- (2008) Takatsugu Okegawa et al. JOURNAL OF UROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started